What Is Facial Bone Resorption or Menopause Face?

The Facial Skeleton Is Not Static

The bones of your face remodel continuously throughout life. Unlike long bones that primarily lose density from within (endosteal resorption), facial bones lose volume from the outer surface (periosteal resorption), which directly changes facial contour and shape.

Robert Shaw and colleagues at the University of Rochester Medical Center published a landmark CT-based morphometric study showing that the facial skeleton undergoes predictable, site-specific volume loss with aging [1]. The orbital aperture (eye socket opening) increases in area by approximately 19% between the third and seventh decades. The pyriform aperture (nasal opening) widens. The maxillary angle decreases, causing the midface to flatten and retract. These are not soft-tissue phenomena. They are bony structural losses.

The mandible (jawbone) simultaneously loses height and length, with the most pronounced resorption occurring at the gonial angle and the anterior projection of the chin [2]. This creates the characteristic "shrinking jaw" appearance that many women notice in their 50s and 60s. The combination of orbital expansion, midface retraction, and mandibular recession produces the hollowed, deflated appearance that practitioners now refer to as "menopause face."

Why Estrogen Loss Accelerates Facial Bone Resorption

Estrogen is a primary regulator of bone metabolism throughout the skeleton, and the craniofacial bones are no exception. Osteoblasts and osteoclasts in the mandible and maxilla express both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) [3].

When circulating estradiol drops below approximately 20 pg/mL during the menopausal transition, osteoclast activity increases while osteoblast function declines. The result is net bone loss. In the spine and hip, this manifests as osteoporosis. In the face, it manifests as structural volume loss and contour changes.

A 2005 study published in the Journal of Craniofacial Surgery found that postmenopausal women had significantly reduced mandibular cortical width compared to premenopausal controls, and that this reduction correlated with years since menopause [4]. The rate of mandibular bone mineral density loss has been estimated at approximately 1-1.5% per year in untreated postmenopausal women.

The WHI Observational Study data demonstrated that women with lower bone mineral density (BMD) at the hip also had measurably greater facial aging scores, suggesting a systemic estrogen-mediated mechanism linking skeletal health to facial appearance [5]. This is not coincidence. The same hormonal deficiency that causes vertebral fractures also causes facial deflation.

Specific Anatomic Sites of Facial Bone Loss

Not all facial bones resorb equally. CT-based volumetric analyses have identified three critical zones of accelerated postmenopausal bone loss.

The orbital rim. The superomedial and inferolateral orbital rim recede most dramatically. Pessa and colleagues demonstrated that the orbital aperture area increases significantly with age, and that this widening correlates with the appearance of under-eye hollows, tear trough deepening, and lower eyelid laxity [6]. The bone literally pulls away from the eyeball, creating visible concavity.

The maxilla. The anterior surface of the maxilla resorbs posteriorly and inferiorly. This causes the midface to flatten, the nasolabial folds to deepen, and the upper lip to lose support. The pyriform aperture widens, contributing to nasal tip drooping as the bony foundation shrinks.

The mandible. The mandibular body loses height, the gonial angle obtusifies, and the chin projects less anteriorly. A 2011 study in Plastic and Reconstructive Surgery confirmed that mandibular length and height decrease significantly between the young (20-40), middle (41-64), and old (65+) age groups, with the most accelerated changes occurring in women after menopause [7].

The combined effect is architectural. When the bony scaffold shrinks, the overlying soft tissue (fat pads, muscle, skin) has less structural support. Fat pads descend. Skin sags. The face appears to melt downward and inward. This is why volume loss in the aging face cannot be fully explained by fat atrophy or skin laxity alone.

How Menopause Face Differs From Normal Aging

All adults lose some facial bone volume after age 40. The distinction is speed. Postmenopausal women experience an acceleration of craniofacial resorption that parallels the well-documented 2-3% annual spinal BMD loss during the first 5-7 years following menopause [8].

Men also experience facial bone loss, but at a slower, more linear rate because testosterone (and its aromatization to estradiol) declines gradually rather than precipitously. A comparative imaging study found that women showed significantly greater orbital aperture enlargement and maxillary resorption than age-matched men in the 50-70 age range [1].

The clinical signs of menopause face include: temporal hollowing, brow bone flattening, deepened tear troughs, midface deflation, lengthened upper lip, thinner lip vermilion border, nasolabial fold deepening, marionette line development, jowling, jawline irregularity, and chin recession. Many of these changes occur simultaneously over 3-5 years during the perimenopausal transition, creating the perception of sudden or rapid aging that many women report.

"Patients often describe looking in the mirror and not recognizing themselves," noted Dr. Steven Dayan, a Chicago-based facial plastic surgeon, in a 2019 interview with Dermatologic Surgery. "What they're seeing is the combination of bone loss and soft tissue descent happening simultaneously" [9].

The Role of HRT in Preventing Facial Bone Loss

If estrogen deficiency drives craniofacial resorption, can estrogen replacement prevent it? The evidence is indirect but consistent.

The Women's Health Initiative (WHI) demonstrated that conjugated equine estrogen (CEE) 0.625 mg/day reduced hip fracture risk by 33% over 5.6 years of follow-up [10]. Systemic estrogen replacement preserves bone mineral density throughout the skeleton. There is no physiologic reason why craniofacial bones would be exempt from this protective effect, given that they express the same estrogen receptors.

A 2015 study in Menopause found that women receiving HRT had significantly higher mandibular cortical bone density compared to untreated postmenopausal controls [11]. The treated group also showed less alveolar bone loss (the bone supporting the teeth), which is a clinically relevant marker of mandibular resorption.

Dr. JoAnn Pinkerton, former Executive Director of the North American Menopause Society (NAMS), stated in the 2022 NAMS position statement: "Hormone therapy remains the most effective treatment for the prevention of postmenopausal osteoporosis and associated fractures when initiated close to menopause" [12]. While this statement addresses systemic bone health, the mechanism applies equally to craniofacial bone.

The timing hypothesis matters here. Women who initiate HRT within 5 years of menopause onset (or before age 60) appear to derive the greatest skeletal benefit. Delayed initiation, after significant bone loss has already occurred, may slow further resorption but cannot rebuild lost bone architecture. This "window of opportunity" concept from the WHI and Danish Osteoporosis Prevention Study (DOPS) likely applies to facial bone as well [13].

Measurement and Diagnosis

Facial bone resorption is not routinely measured in clinical practice. Standard dual-energy X-ray absorptiometry (DEXA) scans assess spine and hip BMD but do not image the craniofacial skeleton.

However, several measurement approaches exist for research and specialized clinical contexts:

Cone-beam CT (CBCT). Commonly used in dental practice, CBCT provides detailed three-dimensional imaging of the mandible and maxilla. Mandibular cortical width below 3 mm on panoramic radiography has been proposed as a screening marker for systemic osteoporosis [14].

Panoramic dental radiography. The mandibular cortical index (MCI) classifies the inferior mandibular cortex as normal, mildly eroded, or severely eroded. Studies have shown that MCI grade correlates with systemic BMD and fracture risk [14].

Full facial CT with volumetric analysis. Research protocols use CT-based 3D reconstruction to measure orbital aperture area, pyriform aperture width, maxillary angle, mandibular height, and other craniofacial parameters. This approach documented the age-related changes described in Shaw's 2010 study [1].

For most women, the clinical diagnosis of "menopause face" is made observationally. Rapid-onset facial volume loss in a perimenopausal or early postmenopausal woman, particularly if combined with low systemic BMD on DEXA, strongly suggests estrogen-mediated craniofacial resorption.

Treatment and Prevention Strategies

Managing facial bone resorption requires addressing both the underlying cause (estrogen deficiency) and the downstream effects (soft tissue descent, volume loss).

Systemic hormone replacement therapy. Estradiol (transdermal 0.05 mg/day or oral 1-2 mg/day) with progesterone for women with a uterus remains the most physiologically targeted intervention. By maintaining estrogen signaling at craniofacial osteoblasts, HRT may slow or prevent the accelerated bone loss that occurs postmenopausally [12]. The Endocrine Society 2019 guidelines support HRT for bone protection in symptomatic women within 10 years of menopause [15].

Bisphosphonates and denosumab. Alendronate (70 mg/week) and denosumab (60 mg every 6 months) are proven to preserve systemic BMD and reduce fracture risk. However, specific data on craniofacial bone preservation with these agents are limited, and long-term bisphosphonate use carries a small risk of osteonecrosis of the jaw (ONJ), which represents a paradoxical concern for facial bone health [16].

Calcium and vitamin D optimization. Adequate calcium intake (1 to 200 mg/day) and vitamin D levels (target 30-50 ng/mL) are foundational for any bone-preservation strategy. The U.S. Preventive Services Task Force (USPSTF) notes that evidence for supplementation in community-dwelling postmenopausal women is mixed, but deficiency correction is universally recommended [17].

Resistance exercise and mechanical loading. Weight-bearing exercise preserves appendicular and axial bone density. Facial bones do not benefit from systemic exercise loading in the same way, though masticatory function (chewing hard foods) provides localized mechanical stimulus to the mandible and maxilla.

Dermal fillers and structural fat grafting. Hyaluronic acid fillers (e.g., Voluma, Radiesse) placed at the bone-periosteal level can partially compensate for lost skeletal volume. Deep injection at the orbital rim, midface, and jawline creates a "scaffolding effect" that mimics the lost bone contour. This is symptomatic treatment, not disease modification. It does not slow ongoing resorption.

Surgical options. For advanced facial bone loss, facial implants (malar, chin, jawline) or structural fat grafting provide more durable volumization than temporary fillers. These procedures are increasingly being discussed in the context of menopausal facial aging rather than purely cosmetic enhancement.

The Dental Connection

Oral health provides a measurable window into craniofacial bone status. Alveolar bone loss (the bone surrounding tooth roots) is one of the earliest and most clinically apparent manifestations of facial bone resorption.

Postmenopausal women have significantly higher rates of tooth loss, periodontal disease, and edentulism compared to premenopausal women and age-matched men [18]. A meta-analysis published in the Journal of Dental Research confirmed that low systemic BMD is associated with increased clinical attachment loss and alveolar bone height reduction [18].

Several studies have found that HRT users have fewer missing teeth and less alveolar bone loss compared to non-users. The WHI Observational Study reported that current HRT users had 24% fewer tooth loss events over 5 years compared to never-users [19]. This dental protection provides indirect but compelling evidence that estrogen replacement preserves the craniofacial skeleton.

Dentists and periodontists may be among the first clinicians to detect accelerated facial bone loss, as panoramic radiographs taken for routine dental care can reveal mandibular cortical thinning years before a patient notices facial contour changes.

Emerging Research and Future Directions

The field of craniofacial aging is evolving rapidly. Several areas of active investigation may change clinical practice.

Selective estrogen receptor modulators (SERMs). Raloxifene preserves spinal BMD without stimulating the uterus or breast tissue. Whether SERMs provide craniofacial bone protection equivalent to estradiol has not been directly studied, but their mechanism of action (ER agonism in bone) suggests potential benefit [20].

Low-dose transdermal estrogen. Ultra-low-dose estradiol patches (0.014 mg/day) have been shown to preserve spinal BMD in postmenopausal women. Whether this dose provides meaningful craniofacial protection requires investigation.

Sclerostin inhibitors. Romosozumab (Evenity), approved for osteoporosis, is an anabolic bone agent that stimulates new bone formation. Its potential application to craniofacial bone restoration is speculative but intriguing given its mechanism.

AI-based facial aging prediction. Machine learning algorithms are being developed to predict craniofacial bone loss from 2D photographs, potentially enabling earlier intervention. These tools are not yet clinically validated.

The most practical takeaway from current evidence: women who maintain adequate estrogen exposure during the menopausal transition (whether through HRT or other means) likely experience less craniofacial bone resorption than those who do not. The facial skeleton responds to the same hormonal signals as the rest of the skeleton. Starting HRT within the recommended window (within 10 years of menopause or before age 60) provides the strongest theoretical basis for facial bone preservation, though long-term randomized controlled trial data specific to craniofacial outcomes do not yet exist.

Women noticing rapid facial aging during perimenopause should request a DEXA scan to assess systemic bone health and discuss HRT with their physician. A mandibular cortical width measurement on dental panoramic radiography can provide additional craniofacial-specific information at minimal cost.